Drug Indicated For Radiological and Nuclear Emergencies Acquires DCGI Approval

Written By: user

IJCP Editorial Team

Published On: 17 Mar, 2023 4:08 PM | Updated On: 16 May, 2024 12:06 AM

Drug Indicated For Radiological and Nuclear Emergencies Acquires DCGI Approval

Recently, the Drugs Controller General of India (DCGI) has approved Prussian blue insoluble formulations – for radiological and nuclear emergencies.

According to the Defence Ministry, Scott-Edil Pharmacia Ltd, Baddi, Himachal Pradesh, and Skanttr Lifescience LLP, Ahmedabad, Gujarat, were granted the manufacturing and marketing licenses for commercial use of Prussian blue insoluble formulations – developed under the Technology Development Fund (TDF) scheme. The development of these formulations was based on the technology of the Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi – a laboratory of the Defence Research & Development Organisation (DRDO).

The trade name of this drug will be Pru-DecorpTM and PruDecorp-MG. These formulations are utilized for decontaminating Cesium and Thallium and its Active Pharmaceutical Ingredient (API). It is a critical drug used in radiological and nuclear emergencies – based on the World Health Organization (WHO) listings.

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.